Ther Adv Ophthalmol
Plain Language Summary of Publication of the 48-Week Results From PULSAR
Lanzetta P, Korobelnik JF, Heier JS, et al
The plain language summary of the 48-week PULSAR study explains how an 8-mg dose of aflibercept was tested in people with wet age-related macular degeneration. The higher dose, given as infrequently as every 12 or 16 weeks, worked as well as the standard 2-mg dose given every 8 weeks. The study also found the treatment to be generally safe, with no new safety concerns identified.
Previous Article
- • Deep Learning-Assisted Analysis of Biomarker Changes in Therapy-Resistant Neovascular Age-Related Macular Degeneration
- • Real-World Safety and Efficacy of 8 mg Aflibercept in nAMD
- • Case Report: Aflibercept for DME in Vitrectomized Eyes
- • Guideline Recommendations for Optimal Anti-VEGF Therapy in AMD
- • AI-Assisted Fluid Volume Analysis of Treatment-Naive nAMD in the Real World
- • Consecutive Monthly Loading Administrations of Aflibercept 8 Mg for Treatment-Naïve Exudative AMD
- • Outcomes of High-Dose Aflibercept in Exudative nAMD
- • PULSAR: Intravitreal Aflibercept 8 mg in nAMD
- • PHOTON: Intravitreal Aflibercept 8 mg in Diabetic Macular Edema
- • CANDELA: Aflibercept 8 mg in Patients With nAMD
- • Aflibercept 8 mg: Long-Term Outcomes in PULSAR
- • Plain Language Summary of Publication of the 48-Week Results From PULSAR
- • High-Dose Aflibercept for Refractory AMD
